QNRX Quoin Pharmaceuticals
- 0.6800
- -0.0062-0.90%
Quoin Pharmaceuticals News
Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Naz Rahman maintains $Quoin Pharmaceuticals(QNRX.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 27.6% an
Express News | Quoin Pharmaceuticals Signs Research Agreement With University College Cork Encompassing The Development Of Topical Formulations Of Rapamycin
Quoin Pharmaceuticals Announces Signing of Research Agreement With University College Cork (UCC), Ireland
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseasesUCC's proprietary dissolvable microneedles t
Quoin Pharmaceuticals(QNRX.US) Director Sells US$217.4 in Common Stock
$Quoin Pharmaceuticals(QNRX.US)$ Director LANGER DENNIS sold 297 shares of common stock on Jun 7, 2024 at an average price of $0.732 for a total value of $217.4.Source: Announcement What is statement
Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Quoin Pharmaceuticals | 10-Q: Quarterly report
Express News | Quoin Pharmaceuticals Q1 EPS $(1.11) Compared With $(4.09) YoY, Quoin Had Approximately $14.7M In Cash & Equivalents As Of March 31, 2024
Quoin Pharmaceuticals 4Q Loss/Shr $1.11 >QNRX
Quoin Pharmaceuticals 4Q Loss/Shr $1.11 >QNRX
Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and Intern
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studiesU.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2
Quoin Pharmaceuticals Received Written Notice From Nasdaq Regarding Minimum Bid Price Requirement
Quoin Pharmaceuticals Received Written Notice From Nasdaq Regarding Minimum Bid Price Requirement
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan dise
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Express News | Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4
Quoin Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 327.76% Maxim Group $15 → $4 Maintains Buy 09/07/2022 2038.81% Alliance Global Partners → $20 I
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript
Earnings Call: Quoin Pharmaceuticals Reports Q4 Progress and Outlook
Earnings Call Summary | Quoin Pharmaceuticals(QNRX.US) Q4 2023 Earnings Conference
The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:Financial Performance:Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and
Quoin Pharmaceuticals: Q4 Earnings Insights
Quoin Pharmaceuticals (NASDAQ:QNRX) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsQuoin Pharmaceuticals be
Analysis
Price Target
No Data
